New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
04:34 EDTHUN, CHTP Stocks with implied volatility movement; CHTP HUN
Stocks with implied volatility movement; Chelsea Therapeutics (CHTP) 242, Huntsman (HUN) 30 according to iVolatility.
News For CHTP;HUN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
16:41 EDTHUNHuntsman furthers its global Pigments and Additives Business restructuring
Huntsman announced its plan to restructure its Color Pigments business, another step in its plan to significantly restructure its global Pigments and Additives business. The restructuring of Color Pigments includes an expected headcount reduction of 120 positions and will deliver $20M by mid-2016 toward the total synergies expected of the global Pigments and Additives restructuring plan announced in December. The initial phase of restructuring will include site closures, cost reduction initiatives and a move to centralized shared services. Huntsman CEO Peter R. Huntsman stated, "We are well on track to deliver more than $140M in total synergies, with $60M of that to be achieved in 2015. In addition to these savings, we have announced a plan to close the black end of our TiO2 plant in Calais, France that will generate $35M of annual savings."
February 24, 2015
07:30 EDTHUNJPMorgan to hold a conference
Global High Yield & Leveraged Finance Conference is being held in Miami Beach, FL on February 23-25 with webcasted company presentations to begin on February 24 at 7:40 am; not all company presentations may be webcasted. Webcast Link
February 19, 2015
09:59 EDTHUNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:11 EDTHUNHuntsman downgraded to Neutral from Buy at Citigroup
Citigroup downgraded Huntsman to Neutral citing a lack of catalysts amid a delayed TiO2 recovery, unfavorable currency moves and cash charges limiting free cash flow generation. Citi lowered its price target for shares to $25 from $31 following Huntsman's Q4 results.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use